S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
NASDAQ:CRBU

Caribou Biosciences (CRBU) Stock Forecast, Price & News

$4.78
+0.05 (+1.06%)
(As of 09/29/2023 08:52 PM ET)
Compare
Today's Range
$4.76
$4.95
50-Day Range
$4.69
$7.31
52-Week Range
$3.96
$11.52
Volume
897,700 shs
Average Volume
1.60 million shs
Market Capitalization
$422.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.33

Caribou Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
430.0% Upside
$25.33 Price Target
Short Interest
Bearish
10.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Caribou Biosciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.61) to ($1.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

782nd out of 968 stocks

Biological Products, Except Diagnostic Industry

129th out of 161 stocks


CRBU stock logo

About Caribou Biosciences (NASDAQ:CRBU) Stock

Caribou Biosciences, Inc. is a cutting-edge biopharmaceutical company headquartered in Berkeley, California. Founded in 2011 by Dr. Rachel E. Haurwitz and other prominent scientists, the company is a leader in the field of genome-editing therapies. Caribou utilizes CRISPR-Cas technology to develop precision cell therapies for patients suffering from hematologic malignancies and solid tumors. The company's vision is to revolutionize the treatment landscape for devastating diseases by providing innovative and personalized therapies.

Caribou Biosciences' journey began as a spinoff from research conducted at the University of California, Berkeley, where Dr. Haurwitz and her colleagues worked on harnessing the CRISPR-Cas system for advanced gene-editing applications. Leveraging their expertise, the team established Caribou to explore the potential of genome editing in developing transformative therapeutics.

The company is committed to pushing the boundaries of science and medicine, focusing on creating precision cell therapies that target specific genetic mutations in patients' cells. By modifying these cells, Caribou aims to enhance antitumor activity and provide tailored treatments to address the unique genetic characteristics of each patient's disease.

Caribou Biosciences operates in the biological products industry, specializing in genome-editing therapies. The company's dedication to research and innovation has positioned it as a key player in the field, with significant potential to impact the future of medical treatments.

The company's mission statement revolves around the core belief in the power of genome-editing technology to unlock new possibilities for disease treatment and patient care. Caribou is committed to advancing its pipeline of precision cell therapies and translating cutting-edge science into transformative solutions for patients worldwide.

The leadership team at Caribou Biosciences comprises accomplished professionals with extensive expertise in the biopharmaceutical and scientific domains. Dr. Rachel E. Haurwitz, who co-founded the company and serves as the Chief Executive Officer, President, and Director. With a Ph.D. in Molecular and Cell Biology from UC Berkeley, Dr. Haurwitz was pivotal in developing CRISPR-based gene-editing technologies. Assisting Dr. Haurwitz is Ms. Ruhi A. Khan, the Chief Business Officer responsible for driving strategic partnerships and business development initiatives. Ms. Khan brings a wealth of experience in the biopharmaceutical industry and has been instrumental in shaping Caribou's collaborations. Dr. Syed Ali-aamir Rizvi serves as the Chief Medical Officer, contributing his expertise in clinical development and medical affairs. With a strong background in hematology and oncology, Dr. Rizvi is critical in guiding the clinical progress of Caribou's precision cell therapies. The management team's collective experience, dedication to innovation, and scientific prowess have propelled Caribou Biosciences to the forefront of the genome-editing industry.

Caribou Biosciences has demonstrated steady revenue growth over the past few years. However, the company is operating at a loss, with a net negative income of close to $100 million. The negative net profit margins result from substantial operating expenses associated with advancing the pipeline of precision cell therapies. Caribou Biosciences' innovative approach to precision cell therapies and its pioneering work in genome editing have garnered investor interest and positive sentiment, contributing to the stock's potential upside.

The stock performance of Caribou Biosciences is subject to various factors, including market conditions, investor sentiment, and news related to the company's progress. Investors closely monitor the company's milestones, clinical trial results, and partnership agreements, which can significantly impact the stock price.

Caribou Biosciences operates in the highly competitive field of biopharmaceuticals, focusing on genome-editing therapies. The broader industry has witnessed significant advancements in CRISPR technology, with various companies vying to develop precision cell therapies. Caribou's competitive advantage lies in its patented Cas12a chRDNA technology, which enables superior precision in genome editing and the development of armored cell therapies.

The company's pipeline of precision cell therapies presents promising growth opportunities. With its CAR-T and CAR-NK platforms targeting hematologic malignancies and solid tumors, Caribou aims to cater to patients with critical medical needs. The company's dedication to scientific excellence and pioneering research positions it well to capitalize on the potential of genome-editing therapies.

Caribou Biosciences faces several potential risks and challenges common to clinical-stage biopharmaceutical companies. These include uncertainties in clinical trials, regulatory approval processes, and market competition. However, Caribou's risk management strategies and scientific expertise serve as potential mitigating factors.

CRBU Price History

CRBU Stock News Headlines

How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
3 Clever Tricks to Find Winning Biotech Stocks
RBC Capital Reaffirms Their Buy Rating on Caribou Biosciences (CRBU)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Caribou Biosciences (CRBU) Receives a Buy from H.C. Wainwright
Where Caribou Biosciences Stands With Analysts
Caribou Biosciences (NASDAQ: CRBU)
See More Headlines
Receive CRBU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CRBU Company Calendar

Last Earnings
8/08/2023
Today
10/01/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRBU
Fax
N/A
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.33
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+430.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-99,420,000.00
Net Margins
-780.23%
Pretax Margin
-779.74%

Debt

Sales & Book Value

Annual Sales
$13.85 million
Book Value
$4.93 per share

Miscellaneous

Free Float
79,898,000
Market Cap
$422.03 million
Optionable
Not Optionable
Beta
1.98
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Rachel E. Haurwitz Ph.D.Dr. Rachel E. Haurwitz Ph.D. (Age 37)
    Co-Founder, CEO, Pres & Director
    Comp: $833.47k
  • Ms. Ruhi A. Khan M.B.A. (Age 48)
    Chief Bus. Officer
    Comp: $573.9k
  • Dr. Syed Ali-aamir Rizvi M.D. (Age 56)
    Chief Medical Officer
    Comp: $677.08k
  • Mr. Jason V. O'Byrne M.B.A. (Age 54)
    CFO & Principal Accounting Officer
  • Mr. Daniel Poon
    VP of Operations & Information Technology
  • Dr. Justin Skoble
    VP of Technical Operations
  • Dr. Steven B. Kanner Ph.D. (Age 64)
    Chief Scientific Officer
  • Ms. Amy Figueroa C.F.A.
    VP of Investor Relations & Corp. Communications
  • Ms. Barbara G. McClung Esq.Ms. Barbara G. McClung Esq. (Age 68)
    J.D., Chief Legal Officer & Corp. Sec.
  • Ms. Cindy Hayashi
    VP of HR













CRBU Stock - Frequently Asked Questions

Should I buy or sell Caribou Biosciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Caribou Biosciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRBU shares.
View CRBU analyst ratings
or view top-rated stocks.

What is Caribou Biosciences' stock price forecast for 2023?

4 brokers have issued 1-year price objectives for Caribou Biosciences' stock. Their CRBU share price forecasts range from $19.00 to $32.00. On average, they predict the company's stock price to reach $25.33 in the next twelve months. This suggests a possible upside of 430.0% from the stock's current price.
View analysts price targets for CRBU
or view top-rated stocks among Wall Street analysts.

How have CRBU shares performed in 2023?

Caribou Biosciences' stock was trading at $6.28 at the start of the year. Since then, CRBU shares have decreased by 23.9% and is now trading at $4.78.
View the best growth stocks for 2023 here
.

Are investors shorting Caribou Biosciences?

Caribou Biosciences saw a increase in short interest in September. As of September 15th, there was short interest totaling 8,210,000 shares, an increase of 20.9% from the August 31st total of 6,790,000 shares. Based on an average daily trading volume, of 3,430,000 shares, the short-interest ratio is presently 2.4 days. Approximately 10.8% of the shares of the stock are sold short.
View Caribou Biosciences' Short Interest
.

When is Caribou Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our CRBU earnings forecast
.

How were Caribou Biosciences' earnings last quarter?

Caribou Biosciences, Inc. (NASDAQ:CRBU) issued its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.01. The company earned $3.76 million during the quarter, compared to analyst estimates of $3.45 million. Caribou Biosciences had a negative trailing twelve-month return on equity of 37.93% and a negative net margin of 780.23%.

When did Caribou Biosciences IPO?

(CRBU) raised $202 million in an IPO on Friday, July 23rd 2021. The company issued 13,500,000 shares at $14.00-$16.00 per share.

What is Caribou Biosciences' stock symbol?

Caribou Biosciences trades on the NASDAQ under the ticker symbol "CRBU."

How do I buy shares of Caribou Biosciences?

Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Caribou Biosciences' stock price today?

One share of CRBU stock can currently be purchased for approximately $4.78.

How much money does Caribou Biosciences make?

Caribou Biosciences (NASDAQ:CRBU) has a market capitalization of $422.03 million and generates $13.85 million in revenue each year. The company earns $-99,420,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis.

How many employees does Caribou Biosciences have?

The company employs 137 workers across the globe.

How can I contact Caribou Biosciences?

The official website for the company is cariboubio.com. The company can be reached via phone at 510-982-6030 or via email at investor.relations@cariboubio.com.

This page (NASDAQ:CRBU) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -